Holly E Janes

List of Publications by Year
in descending order

59 papers	13,422 citations	218381 26 h-index	138251 58 g-index
65 all docs	65 docs citations	65 times ranked	21180 citing authors

#	Article	IF	Citations
1	Evaluating Vaccine Efficacy Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clinical Infectious Diseases, 2022, 74, 544-552.	2.9	9
2	Discussion on â€œEstimating vaccine efficacy over time after a randomized study is unblindedâ€• by Anastasios A. Tsiatis and Marie Davidian. Biometrics, 2022, 78, 841-843.	0.8	1
3	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. Open Forum Infectious Diseases, 2022, 9, ofac124.	0.4	25
4	Analysis of the HIV Vaccine Trials Network 702 Phase 2bâ€“3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. Journal of Infectious Diseases, 2022, 226, 246-257.	1.9	11
5	Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. Annals of Internal Medicine, 2022, 175, 1258-1265.	2.0	63
6	Efficient nonparametric inference on the effects of stochastic interventions under twoâ€•phase sampling, with applications to vaccine efficacy trials. Biometrics, 2021, 77, 1241-1253.	0.8	15
7	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine, 2021, 384, 403-416.	13.9	7,910
8	Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120â€“MF59 in Adults. New England Journal of Medicine, 2021, 384, 1089-1100.	13.9	144
9	Quantifying the Impact of Lifting Community Nonpharmaceutical Interventions for COVID-19 During Vaccination Rollout in the United States. Open Forum Infectious Diseases, 2021, 8, ofab341.	0.4	6
10	Optimizing vaccine allocation for COVID-19 vaccines shows the potential role of single-dose vaccination. Nature Communications, 2021, 12, 3449.	5.8	101
11	RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. Virus Evolution, 2021, 7, veab057.	2.2	2
12	COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact. Scientific Reports, 2021, 11, 15531.	1.6	70
13	A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. Annals of Internal Medicine, 2021, 174, 1118-1125.	2.0	15
14	Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission. Viruses, 2021, 13, 1921.	1.5	10
15	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. New England Journal of Medicine, 2021, 385, 1774-1785.	13.9	402
16	Methods for comparing durability of immune responses between vaccine regimens in early-phase trials. Statistical Methods in Medical Research, 2020, 29, 78-93.	0.7	1
17	The association of Î±4Î²7 expression with HIV acquisition and disease progression in people who inject drugs and men who have sex with men: Case control studies. EBioMedicine, 2020, 62, 103102.	2.7	2
18	Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. Scientific Reports, 2020, 10, 13031.	1.6	10

#	Article	IF	Citations
19	Designing HIV Vaccine Efficacy Trials in the Context of Highly Effective Non-vaccine Prevention Modalities. Statistics in Biosciences, 2020, 12, 468-494.	0.6	5
20	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. PLoS ONE, 2020, 15, e0226803.	1.1	16
21	Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial. Journal of Virology, 2019, 93, .	1.5	26
22	Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors. PLoS ONE, 2019, 14, e0222183.	1.1	1
23	Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. Lancet HIV,the, 2019, 6, e737-e749.	2.1	43
24	Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials. Lancet HIV,the, 2019, 6, e475-e482.	2.1	19
25	Designing the Next Generation of HIV Prevention Efficacy Trials: Synopsis of a 2018 Symposium. Statistical Communications in Infectious Diseases, 2019, 11, .	0.2	3
26	Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. Journal of Infectious Diseases, 2018, 217, 1280-1288.	1.9	32
27	Evaluation of biomarkers for treatment selection using individual participant data from multiple clinical trials. Statistics in Medicine, 2018, 37, 1439-1453.	0.8	4
28	A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial Infection by Mosquito Bites and Direct Venous Inoculation. Journal of Infectious Diseases, 2018, 217, 693-702.	1.9	42
29	Case-only Approach to Identifying Markers Predicting Treatment Effects on the Relative Risk Scale. Biometrics, 2018, 74, 753-763.	0.8	9
30	Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa. AIDS Research and Human Retroviruses, 2018, 34, 645-656.	0.5	23
31	Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials. Vaccine, 2017, 35, 1184-1193.	1.7	9
32	Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. Journal of Infectious Diseases, 2017, 215, 1376-1385.	1.9	59
33	Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer. Contemporary Clinical Trials, 2017, 63, 30-39.	0.8	4
34	First things first: risk model performance metrics should reflect the clinical application. Statistics in Medicine, 2017, 36, 4503-4508.	0.8	10
35	Power/sample size calculations for assessing correlates of risk in clinical efficacy trials. Statistics in Medicine, 2016, 35, 3745-3759.	0.8	8
36	Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 606-608.	0.9	81

#	Article	IF	Citations
37	Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate Use. Journal of Clinical Oncology, 2016, 34, 2534-2540.	0.8	392
38	Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. Current Opinion in Virology, 2016, 17, 57-65.	2.6	14
39	Designing a study to evaluate the benefit of a biomarker for selecting patient treatment. Statistics in Medicine, 2015, 34, 3503-3515.	0.8	11
40	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. PLoS ONE, 2015, 10, e0136626.	1.1	23
41	Use of placebos in Phase 1 preventive HIV vaccine clinical trials. Vaccine, 2015, 33, 749-752.	1.7	2
42	The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment. Journal of the National Cancer Institute, 2015, 107, djv157.	3.0	28
43	HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. Nature Medicine, 2015, 21, 1139-1141.	15.2	50
44	An Approach to Evaluating and Comparing Biomarkers for Patient Treatment Selection. International Journal of Biostatistics, 2014, 10, 99-121.	0.4	47
45	Rejoinder: Combining biomarkers to optimize patient treatment recommendations. Biometrics, 2014, 70, 719-720.	0.8	3
46	Combining biomarkers to optimize patient treatment recommendations. Biometrics, 2014, 70, 695-707.	0.8	58
47	A Framework for Evaluating Markers Used to Select Patient Treatment. Medical Decision Making, 2014, 34, 159-167.	1.2	26
48	Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial. Journal of Virology, 2014, 88, 8242-8255.	1.5	55
49	FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. Journal of Clinical Investigation, 2014, 124, 3879-3890.	3.9	99
50	Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. New England Journal of Medicine, 2013, 369, 2083-2092.	13.9	518
51	In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Nonvaccine Prevention Modalities. AIDS Research and Human Retroviruses, 2013, 29, 1513-1523.	0.5	19
52	Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection. Journal of Infectious Diseases, 2013, 208, 1231-1239.	1.9	73
53	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. New England Journal of Medicine, 2012, 366, 1275-1286.	13.9	1,699
54	Assessing Treatmentâ€Selection Markers using a Potential Outcomes Framework. Biometrics, 2012, 68, 687-696.	0.8	46

#	Article	IF	Citations
55	Measuring the Performance of Markers for Guiding Treatment Decisions. Annals of Internal Medicine, 2011, 154, 253.	2.0	120
56	On quantifying the magnitude of confounding. Biostatistics, 2010, 11, 572-582.	0.9	32
57	Statistical Analysis of Air Pollution Panel Studies: An Illustration. Annals of Epidemiology, 2008, 18, 792-802.	0.9	29
58	HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a caseâ€“cohort analysis. Lancet, The, 2008, 372, 1894-1905.	6.3	670
59	Adjusting for Covariates in Studies of Diagnostic, Screening, or Prognostic Markers: An Old Concept in a New Setting. American Journal of Epidemiology, 2008, 168, 89-97.	1.6	169